BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 2007;337:1-24. [PMID: 17475423 DOI: 10.1016/j.ijpharm.2007.03.025] [Cited by in Crossref: 341] [Cited by in F6Publishing: 294] [Article Influence: 22.7] [Reference Citation Analysis]
Number Citing Articles
1 Rastogi A, Singh A, Naik K, Mishra A, Chaudhary S, Manohar R, Singh Parmar A. A systemic review on liquid crystals, nanoformulations and its application for detection and treatment of SARS - CoV- 2 (COVID - 19). J Mol Liq 2022;362:119795. [PMID: 35832289 DOI: 10.1016/j.molliq.2022.119795] [Reference Citation Analysis]
2 Inoue D, Yamashita A, To H. Formulation and In Vitro Characterization of a Vacuum-Dried Drug–Polymer Thin Film for Intranasal Application. Polymers 2022;14:2954. [DOI: 10.3390/polym14142954] [Reference Citation Analysis]
3 Lo W, Wang Y, Chen EH, Wang S, Chen L, Chen RP. Biodistribution analysis of an intranasal-delivered peptide by the nanoSPECT/CT imaging. Journal of Drug Delivery Science and Technology 2022;73:103454. [DOI: 10.1016/j.jddst.2022.103454] [Reference Citation Analysis]
4 Awad R, Avital A, Sosnik A. Polymeric nanocarriers for nose-to-brain drug delivery in neurodegenerative diseases and neurodevelopmental disorders. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.07.003] [Reference Citation Analysis]
5 Lofts A, Abu-Hijleh F, Rigg N, Mishra RK, Hoare T. Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs. CNS Drugs 2022. [PMID: 35759210 DOI: 10.1007/s40263-022-00930-4] [Reference Citation Analysis]
6 Tai J, Han M, Lee D, Park I, Lee SH, Kim TH. Different Methods and Formulations of Drugs and Vaccines for Nasal Administration. Pharmaceutics 2022;14:1073. [DOI: 10.3390/pharmaceutics14051073] [Reference Citation Analysis]
7 Lu S, Li K, Yang Y, Wang Q, Yu Y, Wang Z, Luan Z. Optimization of an Intranasal Route for the Delivery of Human Neural Stem Cells to Treat a Neonatal Hypoxic-Ischemic Brain Injury Rat Model. Neuropsychiatr Dis Treat 2022;18:413-26. [PMID: 35495583 DOI: 10.2147/NDT.S350586] [Reference Citation Analysis]
8 Qizilbash FF, Ashhar MU, Zafar A, Qamar Z, Annu, Ali J, Baboota S, Ghoneim MM, Alshehri S, Ali A. Thymoquinone-Enriched Naringenin-Loaded Nanostructured Lipid Carrier for Brain Delivery via Nasal Route: In Vitro Prospect and In Vivo Therapeutic Efficacy for the Treatment of Depression. Pharmaceutics 2022;14:656. [DOI: 10.3390/pharmaceutics14030656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Yokel RA. Direct nose to the brain nanomedicine delivery presents a formidable challenge. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2022;14:e1767. [PMID: 34957707 DOI: 10.1002/wnan.1767] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Jo S, Sun I, Ahn C, Lee S, Kim K. Recent Trend of Ultrasound-Mediated Nanoparticle Delivery for Brain Imaging and Treatment. ACS Appl Mater Interfaces. [DOI: 10.1021/acsami.1c22803] [Reference Citation Analysis]
11 Chen M, Lei B, Wang M, Sun H, Zhang X, Shi J, Fan J, Yao Q, Du S, Qu H, Cheng Y, Ma S, Zhang M, Zhan S. Using PCG-Arginine nanoparticle mediated intranasal delivery of dynorphin A (1–8) to improve neuroprotection in MCAO rats. Journal of Drug Delivery Science and Technology 2022;68:103059. [DOI: 10.1016/j.jddst.2021.103059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Blumberger D, Knyahnytska Y, Kaster T, Voineskos D, Trevizol A, Zomorrodi R. Safety, clinical and neurophysiological effects of intranasal ketamine in ECT non-responders: an open-label clinical trial. Pilot Study. Research Protocol. JMIR Res Protoc 2021. [PMID: 34882570 DOI: 10.2196/30163] [Reference Citation Analysis]
13 Shankar J, K.m G, Wilson B. Potential applications of nanomedicine for treating Parkinson's disease. Journal of Drug Delivery Science and Technology 2021;66:102793. [DOI: 10.1016/j.jddst.2021.102793] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Maigler F, Ladel S, Flamm J, Gänger S, Kurpiers B, Kiderlen S, Völk R, Hamp C, Hartung S, Spiegel S, Soleimanizadeh A, Eberle K, Hermann R, Krainer L, Pitzer C, Schindowski K. Selective CNS Targeting and Distribution with a Refined Region-Specific Intranasal Delivery Technique via the Olfactory Mucosa. Pharmaceutics 2021;13:1904. [PMID: 34834319 DOI: 10.3390/pharmaceutics13111904] [Reference Citation Analysis]
15 Raya-Tonetti F, Müller M, Sacur J, Kitazawa H, Villena J, Vizoso-Pinto MG. Novel LysM motifs for antigen display on lactobacilli for mucosal immunization. Sci Rep 2021;11:21691. [PMID: 34737363 DOI: 10.1038/s41598-021-01087-8] [Reference Citation Analysis]
16 Casula E, Letizia Manca M, Manconi M. An integrative review on the uses of plant-derived bioactives formulated in conventional and innovative dosage forms for the local treatment of damaged nasal cavity. Int J Pharm 2021;610:121229. [PMID: 34715259 DOI: 10.1016/j.ijpharm.2021.121229] [Reference Citation Analysis]
17 Herman S, Fishel I, Offen D. Intranasal delivery of mesenchymal stem cells-derived extracellular vesicles for the treatment of neurological diseases. Stem Cells 2021. [PMID: 34520591 DOI: 10.1002/stem.3456] [Reference Citation Analysis]
18 Yayehrad AT, Siraj EA, Wondie GB, Alemie AA, Derseh MT, Ambaye AS. Could Nanotechnology Help to End the Fight Against COVID-19? Review of Current Findings, Challenges and Future Perspectives. Int J Nanomedicine 2021;16:5713-43. [PMID: 34465991 DOI: 10.2147/IJN.S327334] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Rabinowicz AL, Carrazana E, Maggio ET. Improvement of Intranasal Drug Delivery with Intravail® Alkylsaccharide Excipient as a Mucosal Absorption Enhancer Aiding in the Treatment of Conditions of the Central Nervous System. Drugs R D 2021;21:361-9. [PMID: 34435339 DOI: 10.1007/s40268-021-00360-5] [Reference Citation Analysis]
20 Upadhaya PG, Pulakkat S, Patravale VB. Nose-to-brain delivery: exploring newer domains for glioblastoma multiforme management. Drug Deliv Transl Res 2020;10:1044-56. [PMID: 32221847 DOI: 10.1007/s13346-020-00747-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
21 Rivelli GG, Perez AC, Silva PHR, Gomes ECL, Moreira CPS, Tamashiro E, Valera FCP, Anselmo-Lima WT, Pianetti GA, Silva-Cunha A. Biodegradable Electrospun Nanofibers: A New Approach For Rhinosinusitis Treatment. Eur J Pharm Sci 2021;163:105852. [PMID: 33862240 DOI: 10.1016/j.ejps.2021.105852] [Reference Citation Analysis]
22 Asdaq SMB, Ikbal AMA, Sahu RK, Bhattacharjee B, Paul T, Deka B, Fattepur S, Widyowati R, Vijaya J, Al Mohaini M, Alsalman AJ, Imran M, Nagaraja S, Nair AB, Attimarad M, Venugopala KN. Nanotechnology Integration for SARS-CoV-2 Diagnosis and Treatment: An Approach to Preventing Pandemic. Nanomaterials (Basel) 2021;11:1841. [PMID: 34361227 DOI: 10.3390/nano11071841] [Reference Citation Analysis]
23 Clementino AR, Pellegrini G, Banella S, Colombo G, Cantù L, Sonvico F, Del Favero E. Structure and Fate of Nanoparticles Designed for the Nasal Delivery of Poorly Soluble Drugs. Mol Pharm 2021;18:3132-46. [PMID: 34259534 DOI: 10.1021/acs.molpharmaceut.1c00366] [Reference Citation Analysis]
24 Girnar GA, Mahajan HS. Cerebral ischemic stroke and different approaches for treatment of stroke. Futur J Pharm Sci 2021;7. [DOI: 10.1186/s43094-021-00289-1] [Reference Citation Analysis]
25 Akita T, Kimura R, Akaguma S, Nagai M, Nakao Y, Tsugane M, Suzuki H, Oka JI, Yamashita C. Usefulness of cell-penetrating peptides and penetration accelerating sequence for nose-to-brain delivery of glucagon-like peptide-2. J Control Release 2021;335:575-83. [PMID: 34116136 DOI: 10.1016/j.jconrel.2021.06.007] [Reference Citation Analysis]
26 Chari S, Sridhar K, Walenga R, Kleinstreuer C. Computational analysis of a 3D mucociliary clearance model predicting nasal drug uptake. Journal of Aerosol Science 2021;155:105757. [DOI: 10.1016/j.jaerosci.2021.105757] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
27 Alami-Milani M, Salatin S, Rayeni FS, Jelvehgari M. Preparation and in vitro evaluation of thermosensitive and mucoadhesive hydrogels for intranasal delivery of phenobarbital sodium. Ther Deliv 2021;12:461-75. [PMID: 34013779 DOI: 10.4155/tde-2021-0022] [Reference Citation Analysis]
28 Erichsen JM, Calva CB, Reagan LP, Fadel JR. Intranasal insulin and orexins to treat age-related cognitive decline. Physiol Behav 2021;234:113370. [PMID: 33621561 DOI: 10.1016/j.physbeh.2021.113370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Agbo CP, Ugwuanyi TC, Ugwuoke WI, McConville C, Attama AA, Ofokansi KC. Intranasal artesunate-loaded nanostructured lipid carriers: A convenient alternative to parenteral formulations for the treatment of severe and cerebral malaria. J Control Release 2021;334:224-36. [PMID: 33894303 DOI: 10.1016/j.jconrel.2021.04.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Bartos C, Varga P, Szabó-Révész P, Ambrus R. Physico-Chemical and In Vitro Characterization of Chitosan-Based Microspheres Intended for Nasal Administration. Pharmaceutics 2021;13:608. [PMID: 33922172 DOI: 10.3390/pharmaceutics13050608] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
31 Nehra G, Andrews S, Rettig J, Gould MN, Haag JD, Howard SP, Thorne RG. Intranasal administration of the chemotherapeutic perillyl alcohol results in selective delivery to the cerebrospinal fluid in rats. Sci Rep 2021;11:6351. [PMID: 33737566 DOI: 10.1038/s41598-021-85293-4] [Reference Citation Analysis]
32 Boroumand H, Badie F, Mazaheri S, Seyedi ZS, Nahand JS, Nejati M, Baghi HB, Abbasi-Kolli M, Badehnoosh B, Ghandali M, Hamblin MR, Mirzaei H. Chitosan-Based Nanoparticles Against Viral Infections. Front Cell Infect Microbiol 2021;11:643953. [PMID: 33816349 DOI: 10.3389/fcimb.2021.643953] [Reference Citation Analysis]
33 Malmros Olsson E, Lönnqvist PA, Stiller CO, Eksborg S, Lundeberg S. Rapid systemic uptake of naloxone after intranasal administration in children. Paediatr Anaesth 2021;31:631-6. [PMID: 33687794 DOI: 10.1111/pan.14175] [Reference Citation Analysis]
34 Kumbhar SA, Kokare CR, Shrivastava B, Gorain B, Choudhury H. Antipsychotic Potential and Safety Profile of TPGS-Based Mucoadhesive Aripiprazole Nanoemulsion: Development and Optimization for Nose-To-Brain Delivery. J Pharm Sci 2021;110:1761-78. [PMID: 33515583 DOI: 10.1016/j.xphs.2021.01.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Yang D. Application of Nanotechnology in the COVID-19 Pandemic. Int J Nanomedicine 2021;16:623-49. [PMID: 33531805 DOI: 10.2147/IJN.S296383] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
36 Keller LA, Merkel O, Popp A. Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv Transl Res 2021. [PMID: 33491126 DOI: 10.1007/s13346-020-00891-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
37 Padmakumar S, Jones G, Pawar G, Khorkova O, Hsiao J, Kim J, Amiji MM, Bleier BS. Minimally Invasive Nasal Depot (MIND) technique for direct BDNF AntagoNAT delivery to the brain. J Control Release 2021;331:176-86. [PMID: 33484777 DOI: 10.1016/j.jconrel.2021.01.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
38 Fuchs S, Ernst AU, Wang L, Shariati K, Wang X, Liu Q, Ma M. Hydrogels in Emerging Technologies for Type 1 Diabetes. Chem Rev 2021;121:11458-526. [DOI: 10.1021/acs.chemrev.0c01062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
39 Boddu SH, Kumari S. Design and In Vitro Evaluation of Intranasal Diazepam for Treating Acute Repetitive Seizures: a Technical Note. J Pharm Innov. [DOI: 10.1007/s12247-020-09519-0] [Reference Citation Analysis]
40 Ansari MA, Chung IM, Rajakumar G, Alzohairy MA, Alomary MN, Thiruvengadam M, Pottoo FH, Ahmad N. Current Nanoparticle Approaches in Nose to Brain Drug Delivery and Anticancer Therapy - A Review. Curr Pharm Des 2020;26:1128-37. [PMID: 31951165 DOI: 10.2174/1381612826666200116153912] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
41 Skulberg AK, Tylleskär I, Braarud AC, Dale J, Heyerdahl F, Mellesmo S, Valberg M, Dale O. NTNU intranasal naloxone trial (NINA-1) study protocol for a double-blind, double-dummy, non-inferiority randomised controlled trial comparing intranasal 1.4 mg to intramuscular 0.8 mg naloxone for prehospital use. BMJ Open 2020;10:e041556. [PMID: 33184084 DOI: 10.1136/bmjopen-2020-041556] [Reference Citation Analysis]
42 Tashima T. Shortcut Approaches to Substance Delivery into the Brain Based on Intranasal Administration Using Nanodelivery Strategies for Insulin. Molecules 2020;25:E5188. [PMID: 33171799 DOI: 10.3390/molecules25215188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
43 Weintraub S, Frishman WH. A Novel Calcium Channel Blocker: Etripamil: What is the Future of Intranasal Drug Delivery in the Treatment of Cardiac Arrhythmias? Cardiol Rev 2021;29:253-8. [PMID: 33060411 DOI: 10.1097/CRD.0000000000000362] [Reference Citation Analysis]
44 Ruiz-Hitzky E, Darder M, Wicklein B, Ruiz-Garcia C, Martín-Sampedro R, Del Real G, Aranda P. Nanotechnology Responses to COVID-19. Adv Healthc Mater 2020;9:e2000979. [PMID: 32885616 DOI: 10.1002/adhm.202000979] [Cited by in Crossref: 69] [Cited by in F6Publishing: 47] [Article Influence: 34.5] [Reference Citation Analysis]
45 Mena-Hernández J, Jung-Cook H, Llaguno-Munive M, García-López P, Ganem-Rondero A, López-Ramírez S, Barragán-Aroche F, Rivera-Huerta M, Mayet-Cruz L. Preparation and Evaluation of Mebendazole Microemulsion for Intranasal Delivery: an Alternative Approach for Glioblastoma Treatment. AAPS PharmSciTech 2020;21:264. [PMID: 32980937 DOI: 10.1208/s12249-020-01805-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
46 Oktay AN, Ilbasmis-Tamer S, Han S, Uludag O, Celebi N. Preparation and in vitro / in vivo evaluation of flurbiprofen nanosuspension-based gel for dermal application. Eur J Pharm Sci 2020;155:105548. [PMID: 32937211 DOI: 10.1016/j.ejps.2020.105548] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
47 Newman L, Rodrigues AF, Jasim DA, Vacchi IA, Ménard-moyon C, Bianco A, Bussy C, Kostarelos K. Nose-to-Brain Translocation and Cerebral Biodegradation of Thin Graphene Oxide Nanosheets. Cell Reports Physical Science 2020;1:100176. [DOI: 10.1016/j.xcrp.2020.100176] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
48 Gurunathan S, Qasim M, Choi Y, Do JT, Park C, Hong K, Kim JH, Song H. Antiviral Potential of Nanoparticles-Can Nanoparticles Fight Against Coronaviruses? Nanomaterials (Basel) 2020;10:E1645. [PMID: 32825737 DOI: 10.3390/nano10091645] [Cited by in Crossref: 39] [Cited by in F6Publishing: 24] [Article Influence: 19.5] [Reference Citation Analysis]
49 Agrawal M, Saraf S, Saraf S, Dubey SK, Puri A, Gupta U, Kesharwani P, Ravichandiran V, Kumar P, Naidu VGM, Murty US, Ajazuddin, Alexander A. Stimuli-responsive In situ gelling system for nose-to-brain drug delivery. J Control Release 2020;327:235-65. [PMID: 32739524 DOI: 10.1016/j.jconrel.2020.07.044] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
50 Fonseca-Santos B, Silva PB, Rigon RB, Sato MR, Chorilli M. Formulating SLN and NLC as Innovative Drug Delivery Systems for Non-Invasive Routes of Drug Administration. Curr Med Chem 2020;27:3623-56. [PMID: 31232233 DOI: 10.2174/0929867326666190624155938] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
51 Salimi A, Gobadian H, Sharif Makhmalzadeh B. Dermal pharmacokinetics of rivastigmine-loaded liposomes: an ex vivo-in vivo correlation study. J Liposome Res 2021;31:246-54. [PMID: 32594811 DOI: 10.1080/08982104.2020.1787440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
52 Salem LH, El-feky GS, Fahmy RH, El Gazayerly ON, Abdelbary A. Coated Lipidic Nanoparticles as a New Strategy for Enhancing Nose-to-Brain Delivery of a Hydrophilic Drug Molecule. Journal of Pharmaceutical Sciences 2020;109:2237-51. [DOI: 10.1016/j.xphs.2020.04.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
53 Shelke S, Pathan I, Shinde G, Agrawal G, Damale M, Chouthe R, Panzade P, Kulkarni D. Poloxamer-Based In Situ Nasal Gel of Naratriptan Hydrochloride Deformable Vesicles for Brain Targeting. BioNanoSci 2020;10:633-48. [DOI: 10.1007/s12668-020-00767-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Kumbhar SA, Kokare CR, Shrivastava B, Gorain B, Choudhury H. Preparation, characterization, and optimization of asenapine maleate mucoadhesive nanoemulsion using Box-Behnken design: In vitro and in vivo studies for brain targeting. Int J Pharm 2020;586:119499. [PMID: 32505580 DOI: 10.1016/j.ijpharm.2020.119499] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
55 Badhe RV, Nipate SS. Nasal Bioadhesive Drug Delivery Systems and Their Applications. In: Mittal K, Bakshi IS, Narang JK, editors. Bioadhesives in Drug Delivery. Wiley; 2020. pp. 259-305. [DOI: 10.1002/9781119640240.ch10] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
56 Tan MSA, Parekh HS, Pandey P, Siskind DJ, Falconer JR. Nose-to-brain delivery of antipsychotics using nanotechnology: a review. Expert Opin Drug Deliv 2020;17:839-53. [PMID: 32343186 DOI: 10.1080/17425247.2020.1762563] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
57 Itani R, Tobaiqy M, Al Faraj A. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients. Theranostics 2020;10:5932-42. [PMID: 32483428 DOI: 10.7150/thno.46691] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 37.5] [Reference Citation Analysis]
58 Di Salvo A, Conti MB, Nannarone S, Bufalari A, Giorgi M, Moretti G, Marenzoni ML, Della Rocca G. Pharmacokinetics and analgesic efficacy of intranasal administration of tramadol in dogs after ovariohysterectomy. Vet Anaesth Analg 2020;47:557-66. [PMID: 32513525 DOI: 10.1016/j.vaa.2019.12.011] [Reference Citation Analysis]
59 Alshweiat A, Csóka I, Tömösi F, Janáky T, Kovács A, Gáspár R, Sztojkov-Ivanov A, Ducza E, Márki Á, Szabó-Révész P, Ambrus R. Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation. Int J Pharm 2020;579:119166. [PMID: 32084574 DOI: 10.1016/j.ijpharm.2020.119166] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
60 Forbes B, Bommer R, Goole J, Hellfritzsch M, De Kruijf W, Lambert P, Caivano G, Regard A, Schiaretti F, Trenkel M, Vecellio L, Williams G, Sonvico F, Scherließ R. A consensus research agenda for optimising nasal drug delivery. Expert Opin Drug Deliv 2020;17:127-32. [PMID: 31928241 DOI: 10.1080/17425247.2020.1714589] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
61 Alshweiat A, Ambrus R, Csoka I. Intranasal Nanoparticulate Systems as Alternative Route of Drug Delivery. Curr Med Chem 2019;26:6459-92. [PMID: 31453778 DOI: 10.2174/0929867326666190827151741] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
62 Thotakura N, Kaushik L, Kumar V, Preet S, Babu PV. Advanced Approaches of Bioactive Peptide Molecules and Protein Drug Delivery Systems. Curr Pharm Des 2018;24:5147-63. [PMID: 30727874 DOI: 10.2174/1381612825666190206211458] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
63 Bahman F, Greish K, Taurin S. Nanotechnology in Insulin Delivery for Management of Diabetes. Pharm Nanotechnol 2019;7:113-28. [PMID: 30907328 DOI: 10.2174/2211738507666190321110721] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
64 Miwa T, Tachii K, Wei F, Kaitsuka T, Tomizawa K. Intranasal Drug Delivery into Mouse Nasal Mucosa and Brain Utilizing Arginine-Rich Cell-Penetrating Peptide-Mediated Protein Transduction. Int J Pept Res Ther 2020;26:1643-50. [DOI: 10.1007/s10989-019-09971-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
65 Bhattacharjee S, Chen J, Landers J, Baker JR. Zwitterionic Surfactant as a Promising Non‐Cytotoxic Carrier for Nanoemulsion‐Based Vaccine Development. ChemistrySelect 2019;4:9027-32. [DOI: 10.1002/slct.201902737] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
66 Di Cola E, Cantu' L, Brocca P, Rondelli V, Fadda GC, Canelli E, Martelli P, Clementino A, Sonvico F, Bettini R, Del Favero E. Novel O/W nanoemulsions for nasal administration: Structural hints in the selection of performing vehicles with enhanced mucopenetration. Colloids Surf B Biointerfaces 2019;183:110439. [PMID: 31473410 DOI: 10.1016/j.colsurfb.2019.110439] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
67 Ladel S, Schlossbauer P, Flamm J, Luksch H, Mizaikoff B, Schindowski K. Improved In Vitro Model for Intranasal Mucosal Drug Delivery: Primary Olfactory and Respiratory Epithelial Cells Compared with the Permanent Nasal Cell Line RPMI 2650. Pharmaceutics 2019;11:E367. [PMID: 31374872 DOI: 10.3390/pharmaceutics11080367] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
68 Le Floc'h J, Lu HD, Lim TL, Démoré C, Prud'homme RK, Hynynen K, Foster FS. Transcranial Photoacoustic Detection of Blood-Brain Barrier Disruption Following Focused Ultrasound-Mediated Nanoparticle Delivery. Mol Imaging Biol 2020;22:324-34. [PMID: 31286352 DOI: 10.1007/s11307-019-01397-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
69 Shevchenko KV, Nagaev IY, Andreeva LA, Shevchenko VP, Myasoedov NF. Stability of Proline-Containing Peptides in Biological Media. Biochem Moscow Suppl Ser B 2019;13:179-201. [DOI: 10.1134/s1990750819030089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
70 Schlachet I, Sosnik A. Mixed Mucoadhesive Amphiphilic Polymeric Nanoparticles Cross a Model of Nasal Septum Epithelium in Vitro. ACS Appl Mater Interfaces 2019;11:21360-71. [PMID: 31124655 DOI: 10.1021/acsami.9b04766] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
71 Triarico S, Capozza MA, Mastrangelo S, Attinà G, Maurizi P, Ruggiero A. Intranasal therapy with opioids for children and adolescents with cancer: results from clinical studies. Support Care Cancer 2019;27:3639-45. [PMID: 31154533 DOI: 10.1007/s00520-019-04854-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
72 Khallaf RA, Aboud HM, Sayed OM. Surface modified niosomes of olanzapine for brain targeting via nasal route; preparation, optimization, and in vivo evaluation. Journal of Liposome Research 2020;30:163-73. [DOI: 10.1080/08982104.2019.1610435] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
73 Shevchenko KV, Nagaev IY, Andreeva LA, Shevchenko VP, Myasoedov NF. Prospects for Intranasal Delivery of Neuropeptides to the Brain. Pharm Chem J 2019;53:89-100. [DOI: 10.1007/s11094-019-01960-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Jazuli I, Annu, Nabi B, Moolakkadath T, Alam T, Baboota S, Ali J. Optimization of Nanostructured Lipid Carriers of Lurasidone Hydrochloride Using Box-Behnken Design for Brain Targeting: In Vitro and In Vivo Studies. J Pharm Sci 2019;108:3082-90. [PMID: 31077685 DOI: 10.1016/j.xphs.2019.05.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
75 Quintana DS, Smerud KT, Andreassen OA, Djupesland PG. Evidence for intranasal oxytocin delivery to the brain: recent advances and future perspectives. Ther Deliv 2018;9:515-25. [PMID: 29943688 DOI: 10.4155/tde-2018-0002] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 13.7] [Reference Citation Analysis]
76 Gaikwad PS, Banerjee R. Nanotechnology-based strategies as novel therapies in gliomas. Ther Deliv 2018;9:571-92. [PMID: 30071804 DOI: 10.4155/tde-2018-0022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Krieter P, Chiang CN, Gyaw S, Skolnick P, Snyder R. Pharmacokinetic Interaction between Naloxone and Naltrexone Following Intranasal Administration to Healthy Subjects. Drug Metab Dispos 2019;47:690-8. [PMID: 30992306 DOI: 10.1124/dmd.118.085977] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
78 Qureshi M, Aqil M, Imam SS, Ahad A, Sultana Y. Formulation and Evaluation of Neuroactive Drug Loaded Chitosan Nanoparticle for Nose to Brain Delivery: In-vitro Characterization and In-vivo Behavior Study. Curr Drug Deliv 2019;16:123-35. [PMID: 30317997 DOI: 10.2174/1567201815666181011121750] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
79 Krieter PA, Chiang CN, Gyaw S, McCann DJ. Comparison of the Pharmacokinetic Properties of Naloxone Following the Use of FDA-Approved Intranasal and Intramuscular Devices Versus a Common Improvised Nasal Naloxone Device. J Clin Pharmacol 2019;59:1078-84. [PMID: 30861160 DOI: 10.1002/jcph.1401] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
80 van de Wiel SMW, Bijsmans ITGW, van Mil SWC, van de Graaf SFJ. Identification of FDA-approved drugs targeting the Farnesoid X Receptor. Sci Rep 2019;9:2193. [PMID: 30778102 DOI: 10.1038/s41598-019-38668-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
81 Zada MH, Kubek M, Khan W, Kumar A, Domb A. Dispersible hydrolytically sensitive nanoparticles for nasal delivery of thyrotropin releasing hormone (TRH). J Control Release 2019;295:278-89. [PMID: 30610951 DOI: 10.1016/j.jconrel.2018.12.050] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
82 Costa C, Moreira JN, Amaral MH, Sousa Lobo JM, Silva AC. Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis. J Control Release 2019;295:187-200. [PMID: 30610952 DOI: 10.1016/j.jconrel.2018.12.049] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 13.7] [Reference Citation Analysis]
83 Jiao J, Zhang L. Influence of Intranasal Drugs on Human Nasal Mucociliary Clearance and Ciliary Beat Frequency. Allergy Asthma Immunol Res 2019;11:306-19. [PMID: 30912321 DOI: 10.4168/aair.2019.11.3.306] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
84 Kim NA, Thapa R, Jeong SH, Bae HD, Maeng J, Lee K, Park K. Enhanced intranasal insulin delivery by formulations and tumor protein-derived protein transduction domain as an absorption enhancer. J Control Release 2019;294:226-36. [PMID: 30557648 DOI: 10.1016/j.jconrel.2018.12.023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
85 Fachel FNS, Schuh RS, Veras KS, Bassani VL, Koester LS, Henriques AT, Braganhol E, Teixeira HF. An overview of the neuroprotective potential of rosmarinic acid and its association with nanotechnology-based delivery systems: A novel approach to treating neurodegenerative disorders. Neurochem Int 2019;122:47-58. [PMID: 30439384 DOI: 10.1016/j.neuint.2018.11.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
86 Nocera AL, Mueller SK, Stephan JR, Hing L, Seifert P, Han X, Lin DT, Amiji MM, Libermann T, Bleier BS. Exosome swarms eliminate airway pathogens and provide passive epithelial immunoprotection through nitric oxide. J Allergy Clin Immunol 2019;143:1525-1535.e1. [PMID: 30442371 DOI: 10.1016/j.jaci.2018.08.046] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
87 Kumar NN, Pizzo ME, Nehra G, Wilken-Resman B, Boroumand S, Thorne RG. Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches. Bioconjug Chem 2018;29:3937-66. [PMID: 30265523 DOI: 10.1021/acs.bioconjchem.8b00548] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
88 Kim JS, Kim MS, Baek IH. Enhanced Bioavailability of Tadalafil after Intranasal Administration in Beagle Dogs. Pharmaceutics 2018;10:E187. [PMID: 30326564 DOI: 10.3390/pharmaceutics10040187] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
89 Ullah I, Chung K, Oh J, Beloor J, Bae S, Lee SC, Lee M, Kumar P, Lee SK. Intranasal delivery of a Fas-blocking peptide attenuates Fas-mediated apoptosis in brain ischemia. Sci Rep 2018;8:15041. [PMID: 30301943 DOI: 10.1038/s41598-018-33296-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
90 Bodratti AM, Alexandridis P. Amphiphilic block copolymers in drug delivery: advances in formulation structure and performance. Expert Opinion on Drug Delivery 2018;15:1085-104. [DOI: 10.1080/17425247.2018.1529756] [Cited by in Crossref: 49] [Cited by in F6Publishing: 26] [Article Influence: 12.3] [Reference Citation Analysis]
91 Singh M, Khan RS, Dine K, Das Sarma J, Shindler KS. Intracranial Inoculation Is More Potent Than Intranasal Inoculation for Inducing Optic Neuritis in the Mouse Hepatitis Virus-Induced Model of Multiple Sclerosis. Front Cell Infect Microbiol 2018;8:311. [PMID: 30234031 DOI: 10.3389/fcimb.2018.00311] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
92 Singh N, Veronese M, O'Doherty J, Sementa T, Bongarzone S, Cash D, Simmons C, Arcolin M, Marsden PK, Gee A, Turkheimer FE. Assessing the feasibility of intranasal radiotracer administration for in brain PET imaging. Nucl Med Biol 2018;66:32-9. [PMID: 30208358 DOI: 10.1016/j.nucmedbio.2018.08.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
93 Giuliani A, Balducci AG, Zironi E, Colombo G, Bortolotti F, Lorenzini L, Galligioni V, Pagliuca G, Scagliarini A, Calzà L, Sonvico F. In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates. Drug Deliv 2018;25:376-87. [PMID: 29382237 DOI: 10.1080/10717544.2018.1428242] [Cited by in F6Publishing: 28] [Reference Citation Analysis]
94 Burk JA, Blumenthal SA, Maness EB. Neuropharmacology of attention. Eur J Pharmacol 2018;835:162-8. [PMID: 30092180 DOI: 10.1016/j.ejphar.2018.08.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
95 Qian S, He L, Wang Q, Wong YC, Mak M, Ho C, Han Y, Zuo Z. Intranasal delivery of a novel acetylcholinesterase inhibitor HLS-3 for treatment of Alzheimer's disease. Life Sciences 2018;207:428-35. [DOI: 10.1016/j.lfs.2018.06.032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
96 Abdelmonem R, El Nabarawi M, Attia A. Development of novel bioadhesive granisetron hydrochloride spanlastic gel and insert for brain targeting and study their effects on rats. Drug Deliv 2018;25:70-7. [PMID: 29228824 DOI: 10.1080/10717544.2017.1413447] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
97 Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule MB, Shoyele SA, Alexander A. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. Journal of Controlled Release 2018;281:139-77. [DOI: 10.1016/j.jconrel.2018.05.011] [Cited by in Crossref: 163] [Cited by in F6Publishing: 143] [Article Influence: 40.8] [Reference Citation Analysis]
98 Guennoun R, Fréchou M, Gaignard P, Liere P, Slama A, Schumacher M, Denier C, Mattern C. Intranasal administration of progesterone: A potential efficient route of delivery for cerebroprotection after acute brain injuries. Neuropharmacology 2019;145:283-91. [PMID: 29885423 DOI: 10.1016/j.neuropharm.2018.06.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
99 Bourganis V, Kammona O, Alexopoulos A, Kiparissides C. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics. Eur J Pharm Biopharm 2018;128:337-62. [PMID: 29733950 DOI: 10.1016/j.ejpb.2018.05.009] [Cited by in Crossref: 97] [Cited by in F6Publishing: 79] [Article Influence: 24.3] [Reference Citation Analysis]
100 Javed H, Shah SNH, Iqbal FM. Formulation Development and Evaluation of Diphenhydramine Nasal Nano-Emulgel. AAPS PharmSciTech 2018;19:1730-43. [PMID: 29569155 DOI: 10.1208/s12249-018-0985-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
101 Fouad SA, Shamma RN, Basalious EB, El-Nabarawi MM, Tayel SA. Novel instantly-dispersible nanocarrier powder system (IDNPs) for intranasal delivery of dapoxetine hydrochloride: in-vitro optimization, ex-vivo permeation studies, and in-vivo evaluation. Drug Dev Ind Pharm 2018;44:1443-50. [PMID: 29614890 DOI: 10.1080/03639045.2018.1459675] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
102 Skulberg AK, Tylleskar I, Nilsen T, Skarra S, Salvesen Ø, Sand T, Loftsson T, Dale O. Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers. Eur J Clin Pharmacol 2018;74:873-83. [PMID: 29568976 DOI: 10.1007/s00228-018-2443-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
103 Taherali F, Varum F, Basit AW. A slippery slope: On the origin, role and physiology of mucus. Adv Drug Deliv Rev 2018;124:16-33. [PMID: 29108861 DOI: 10.1016/j.addr.2017.10.014] [Cited by in Crossref: 80] [Cited by in F6Publishing: 66] [Article Influence: 20.0] [Reference Citation Analysis]
104 Agu RU. Challenges in nasal drug absorption: how far have we come? Ther Deliv 2016;7:495-510. [PMID: 27403632 DOI: 10.4155/tde-2016-0022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
105 Nageeb El-Helaly S, Abd Elbary A, Kassem MA, El-Nabarawi MA. Electrosteric stealth Rivastigmine loaded liposomes for brain targeting: preparation, characterization, ex vivo, bio-distribution and in vivo pharmacokinetic studies. Drug Deliv 2017;24:692-700. [PMID: 28415883 DOI: 10.1080/10717544.2017.1309476] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
106 Pitta SK, Dudhipala N, Narala A, Veerabrahma K. Development of zolmitriptan transfersomes by Box–Behnken design for nasal delivery: in vitro and in vivo evaluation. Drug Development and Industrial Pharmacy 2018;44:484-92. [DOI: 10.1080/03639045.2017.1402918] [Cited by in Crossref: 32] [Cited by in F6Publishing: 18] [Article Influence: 6.4] [Reference Citation Analysis]
107 Liu S, Yang S, Ho PC. Intranasal administration of carbamazepine-loaded carboxymethyl chitosan nanoparticles for drug delivery to the brain. Asian J Pharm Sci 2018;13:72-81. [PMID: 32104380 DOI: 10.1016/j.ajps.2017.09.001] [Cited by in Crossref: 53] [Cited by in F6Publishing: 31] [Article Influence: 10.6] [Reference Citation Analysis]
108 Hernando S, Herran E, Figueiro-silva J, Pedraz JL, Igartua M, Carro E, Hernandez RM. Intranasal Administration of TAT-Conjugated Lipid Nanocarriers Loading GDNF for Parkinson’s Disease. Mol Neurobiol 2018;55:145-55. [DOI: 10.1007/s12035-017-0728-7] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 9.4] [Reference Citation Analysis]
109 Zhang L, Du SY, Lu Y, Liu C, Wu HC, Tian ZH, Wang M, Yang C. Puerarin transport across rat nasal epithelial cells and the influence of compatibility with peoniflorin and menthol. Drug Des Devel Ther 2017;11:2581-93. [PMID: 28919709 DOI: 10.2147/DDDT.S143029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
110 Gufford BT, Ainslie GR, White JR Jr, Layton ME, Padowski JM, Pollack GM, Paine MF. Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. Clin Transl Sci 2017;10:380-6. [PMID: 28504483 DOI: 10.1111/cts.12473] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
111 Zhu H, Lai M, Chen W, Mei D, Zhang F, Liu H, Zhou W. N-acetylaspartylglutamate Inhibits Heroin Self-Administration and Heroin-Seeking Behaviors Induced by Cue or Priming in Rats. Neurosci Bull 2017;33:396-404. [PMID: 28534263 DOI: 10.1007/s12264-017-0140-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
112 Pozzoli M, Traini D, Young PM, Sukkar MB, Sonvico F. Development of a Soluplus budesonide freeze-dried powder for nasal drug delivery. Drug Development and Industrial Pharmacy 2017;43:1510-8. [DOI: 10.1080/03639045.2017.1321659] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
113 Hu Y, Wang Z, Pan S, Fang M, Jiang H, Mao Y, Zhang H, Ji Y, Zhang F, Lin L, Lin Z, Xiao J. Inhibition of endoplasmic reticulum stress is involved in the neuroprotective effect of aFGF in neonatal hypoxic-ischaemic brain injury. Oncotarget 2017;8:60941-53. [PMID: 28977836 DOI: 10.18632/oncotarget.17524] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
114 Yuan D, Yi X, Zhao Y, Poon CD, Bullock KM, Hansen KM, Salameh TS, Farr SA, Banks WA, Kabanov AV. Intranasal delivery of N-terminal modified leptin-pluronic conjugate for treatment of obesity. J Control Release 2017;263:172-84. [PMID: 28344017 DOI: 10.1016/j.jconrel.2017.03.029] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
115 League-Pascual JC, Lester-McCully CM, Shandilya S, Ronner L, Rodgers L, Cruz R, Peer CJ, Figg WD, Warren KE. Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. J Neurooncol 2017;132:401-7. [PMID: 28290002 DOI: 10.1007/s11060-017-2388-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
116 Bailey AM, Baum RA, Horn K, Lewis T, Morizio K, Schultz A, Weant K, Justice SN. Review of Intranasally Administered Medications for Use in the Emergency Department. J Emerg Med 2017;53:38-48. [PMID: 28259526 DOI: 10.1016/j.jemermed.2017.01.020] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
117 Tylleskar I, Skulberg AK, Nilsen T, Skarra S, Jansook P, Dale O. Pharmacokinetics of a new, nasal formulation of naloxone. Eur J Clin Pharmacol 2017;73:555-62. [PMID: 28144724 DOI: 10.1007/s00228-016-2191-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
118 Parhizkar E, Emadi L, Alipour S. Development and evaluation of midazolam in situ nasal gel properties in presence of solubility enhancers at cilia-friendly pH. Macromol Res 2017;25:255-61. [DOI: 10.1007/s13233-017-5031-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
119 Jadhav VR, Patil SB. Development of In Situ Gelling Inserts by Lyophilization for Nasal Delivery of Terbutaline Sulfate. Polymer-Plastics Technology and Engineering 2016;56:1068-75. [DOI: 10.1080/03602559.2016.1253734] [Reference Citation Analysis]
120 Hersh DS, Wadajkar AS, Roberts N, Perez JG, Connolly NP, Frenkel V, Winkles JA, Woodworth GF, Kim AJ. Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier. Curr Pharm Des 2016;22:1177-93. [PMID: 26685681 DOI: 10.2174/1381612822666151221150733] [Cited by in Crossref: 125] [Cited by in F6Publishing: 105] [Article Influence: 20.8] [Reference Citation Analysis]
121 Katare YK, Piazza JE, Bhandari J, Daya RP, Akilan K, Simpson MJ, Hoare T, Mishra RK. Intranasal delivery of antipsychotic drugs. Schizophr Res 2017;184:2-13. [PMID: 27913162 DOI: 10.1016/j.schres.2016.11.027] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
122 Rao M, Agrawal DK, Shirsath C. Thermoreversible mucoadhesive in situ nasal gel for treatment of Parkinson’s disease. Drug Development and Industrial Pharmacy 2017;43:142-50. [DOI: 10.1080/03639045.2016.1225754] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
123 Hawthorne GH, Bernuci MP, Bortolanza M, Tumas V, Issy AC, Del-Bel E. Nanomedicine to Overcome Current Parkinson's Treatment Liabilities: A Systematic Review. Neurotox Res 2016;30:715-29. [PMID: 27581037 DOI: 10.1007/s12640-016-9663-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
124 Upadhyay P, Trivedi J, Pundarikakshudu K, Sheth N. Direct and enhanced delivery of nanoliposomes of anti schizophrenic agent to the brain through nasal route. Saudi Pharm J 2017;25:346-58. [PMID: 28344488 DOI: 10.1016/j.jsps.2016.07.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
125 Linares GR, Chiu C, Scheuing L, Leng Y, Liao H, Maric D, Chuang D. Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington's disease. Experimental Neurology 2016;281:81-92. [DOI: 10.1016/j.expneurol.2016.04.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
126 Bhattacharya S, Maelicke A, Montag D. Nasal Application of the Galantamine Pro-drug Memogain Slows Down Plaque Deposition and Ameliorates Behavior in 5X Familial Alzheimer's Disease Mice. J Alzheimers Dis 2015;46:123-36. [PMID: 25720404 DOI: 10.3233/JAD-142421] [Cited by in Crossref: 24] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
127 Horváth T, Bartos C, Bocsik A, Kiss L, Veszelka S, Deli MA, Újhelyi G, Szabó-Révész P, Ambrus R. Cytotoxicity of Different Excipients on RPMI 2650 Human Nasal Epithelial Cells. Molecules 2016;21:E658. [PMID: 27213303 DOI: 10.3390/molecules21050658] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
128 Wang Y, Li M, Qian S, Zhang Q, Zhou L, Zuo Z, Lee B, Toh M, Ho T. Zolpidem Mucoadhesive Formulations for Intranasal Delivery: Characterization, In Vitro Permeability, Pharmacokinetics, and Nasal Ciliotoxicity in Rats. J Pharm Sci 2016;105:2840-7. [PMID: 27189774 DOI: 10.1016/j.xphs.2016.03.035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
129 El-Setouhy DA, Ibrahim AB, Amin MM, Khowessah OM, Elzanfaly ES. Intranasal haloperidol-loaded miniemulsions for brain targeting: Evaluation of locomotor suppression and in-vivo biodistribution. Eur J Pharm Sci 2016;92:244-54. [PMID: 27154259 DOI: 10.1016/j.ejps.2016.05.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
130 Fouad SA, Shamma RN, Basalious EB, El-nabarawi MA, Tayel SA. Novel instantly-soluble transmucosal matrix (ISTM) using dual mechanism solubilizer for sublingual and nasal delivery of dapoxetine hydrochloride: In-vitro / in-vivo evaluation. International Journal of Pharmaceutics 2016;505:212-22. [DOI: 10.1016/j.ijpharm.2016.04.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
131 Rassu G, Soddu E, Cossu M, Gavini E, Giunchedi P, Dalpiaz A. Particulate formulations based on chitosan for nose-to-brain delivery of drugs. A review. Journal of Drug Delivery Science and Technology 2016;32:77-87. [DOI: 10.1016/j.jddst.2015.05.002] [Cited by in Crossref: 41] [Cited by in F6Publishing: 17] [Article Influence: 6.8] [Reference Citation Analysis]
132 Lee JJ, Shim A, Jeong JY, Lee SY, Ko HJ, Cho HJ. Development of intranasal nanovehicles of itraconazole and their immunological activities for the therapy of rhinovirus infection. Colloids Surf B Biointerfaces 2016;143:336-41. [PMID: 27022874 DOI: 10.1016/j.colsurfb.2016.03.050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
133 Sabilallah M, Fontanaud P, Linck N, Boussadia B, Peyroutou R, Lasgouzes T, Rassendren FA, Marchi N, Hirbec HE. Evidence for Status Epilepticus and Pro-Inflammatory Changes after Intranasal Kainic Acid Administration in Mice. PLoS One 2016;11:e0150793. [PMID: 26963100 DOI: 10.1371/journal.pone.0150793] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
134 Zhao YZ, Jin RR, Yang W, Xiang Q, Yu WZ, Lin Q, Tian FR, Mao KL, Lv CZ, Wáng YX, Lu CT. Using Gelatin Nanoparticle Mediated Intranasal Delivery of Neuropeptide Substance P to Enhance Neuro-Recovery in Hemiparkinsonian Rats. PLoS One 2016;11:e0148848. [PMID: 26894626 DOI: 10.1371/journal.pone.0148848] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
135 Engelhardt L, Röhm M, Mavoungou C, Schindowski K, Schafmeister A, Simon U. First Steps to Develop and Validate a CFPD Model in Order to Support the Design of Nose-to-Brain Delivered Biopharmaceuticals. Pharm Res 2016;33:1337-50. [PMID: 26887679 DOI: 10.1007/s11095-016-1875-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
136 Kovalainen M, Mönkäre J, Riikonen J, Pesonen U, Vlasova M, Salonen J, Lehto VP, Järvinen K, Herzig KH. Novel delivery systems for improving the clinical use of peptides. Pharmacol Rev 2015;67:541-61. [PMID: 26023145 DOI: 10.1124/pr.113.008367] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 8.2] [Reference Citation Analysis]
137 Zhao Y, Lin M, Lin Q, Yang W, Yu X, Tian F, Mao K, Yang J, Lu C, Wong HL. Intranasal delivery of bFGF with nanoliposomes enhances in vivo neuroprotection and neural injury recovery in a rodent stroke model. Journal of Controlled Release 2016;224:165-75. [DOI: 10.1016/j.jconrel.2016.01.017] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 7.3] [Reference Citation Analysis]
138 Rygg A, Longest PW. Absorption and Clearance of Pharmaceutical Aerosols in the Human Nose: Development of a CFD Model. J Aerosol Med Pulm Drug Deliv 2016;29:416-31. [PMID: 26824178 DOI: 10.1089/jamp.2015.1252] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
139 Ahmed TA, Aljaeid BM. Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery. Drug Des Devel Ther 2016;10:483-507. [PMID: 26869768 DOI: 10.2147/DDDT.S99651] [Cited by in Crossref: 275] [Cited by in F6Publishing: 81] [Article Influence: 45.8] [Reference Citation Analysis]
140 Elnaggar YSR, Etman SM, Abdelmonsif DA, Abdallah OY. Intranasal Piperine-Loaded Chitosan Nanoparticles as Brain-Targeted Therapy in Alzheimer's Disease: Optimization, Biological Efficacy, and Potential Toxicity. J Pharm Sci 2015;104:3544-56. [PMID: 28739042 DOI: 10.1002/jps.24557] [Cited by in Crossref: 120] [Cited by in F6Publishing: 102] [Article Influence: 20.0] [Reference Citation Analysis]
141 Chu C, Deng J, Liu L, Cao Y, Wei X, Li J, Man Y. Nanoparticles combined with growth factors: recent progress and applications. RSC Adv 2016;6:90856-72. [DOI: 10.1039/c6ra13636b] [Cited by in Crossref: 12] [Article Influence: 2.0] [Reference Citation Analysis]
142 Gartziandia O, Egusquiaguirre SP, Bianco J, Pedraz JL, Igartua M, Hernandez RM, Préat V, Beloqui A. Nanoparticle transport across in vitro olfactory cell monolayers. Int J Pharm 2016;499:81-9. [PMID: 26721725 DOI: 10.1016/j.ijpharm.2015.12.046] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 6.6] [Reference Citation Analysis]
143 Patel S, Koradia H, Parikh R. Design and development of intranasal in situ gelling system of Midazolam hydrochloride using 32 full factorial design. Journal of Drug Delivery Science and Technology 2015;30:154-62. [DOI: 10.1016/j.jddst.2015.10.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
144 Tlaxca JL, Ellis S, Remmele RL Jr. Live attenuated and inactivated viral vaccine formulation and nasal delivery: potential and challenges. Adv Drug Deliv Rev 2015;93:56-78. [PMID: 25312673 DOI: 10.1016/j.addr.2014.10.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
145 Timbie KF, Mead BP, Price RJ. Drug and gene delivery across the blood-brain barrier with focused ultrasound. J Control Release 2015;219:61-75. [PMID: 26362698 DOI: 10.1016/j.jconrel.2015.08.059] [Cited by in Crossref: 95] [Cited by in F6Publishing: 84] [Article Influence: 13.6] [Reference Citation Analysis]
146 Shinde RL, Bharkad GP, Devarajan PV. Intranasal microemulsion for targeted nose to brain delivery in neurocysticercosis: Role of docosahexaenoic acid. Eur J Pharm Biopharm 2015;96:363-79. [PMID: 26318978 DOI: 10.1016/j.ejpb.2015.08.008] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 6.4] [Reference Citation Analysis]
147 El-setouhy DA, Ahmed S, Badawi AAE, El-nabarawi MA, Sallam N. Preclinical evaluation of dual action intranasal formulation intended for postoperative/cancer associated therapies. European Journal of Pharmaceutical Sciences 2015;76:48-56. [DOI: 10.1016/j.ejps.2015.04.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
148 Al-Ghabeish M, Scheetz T, Assem M, Donovan MD. Microarray Determination of the Expression of Drug Transporters in Humans and Animal Species Used for the Investigation of Nasal Absorption. Mol Pharm 2015;12:2742-54. [PMID: 26106909 DOI: 10.1021/acs.molpharmaceut.5b00103] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
149 Mistry A, Stolnik S, Illum L. Nose-to-Brain Delivery: Investigation of the Transport of Nanoparticles with Different Surface Characteristics and Sizes in Excised Porcine Olfactory Epithelium. Mol Pharmaceutics 2015;12:2755-66. [DOI: 10.1021/acs.molpharmaceut.5b00088] [Cited by in Crossref: 78] [Cited by in F6Publishing: 60] [Article Influence: 11.1] [Reference Citation Analysis]
150 Lioutas VA, Alfaro-Martinez F, Bedoya F, Chung CC, Pimentel DA, Novak V. Intranasal Insulin and Insulin-Like Growth Factor 1 as Neuroprotectants in Acute Ischemic Stroke. Transl Stroke Res 2015;6:264-75. [PMID: 26040423 DOI: 10.1007/s12975-015-0409-7] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 7.1] [Reference Citation Analysis]
151 Shah L, Yadav S, Amiji M. Nanotechnology for CNS delivery of bio-therapeutic agents. Drug Deliv Transl Res 2013;3:336-51. [PMID: 23894728 DOI: 10.1007/s13346-013-0133-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
152 Spetter MS, Hallschmid M. Intranasal Neuropeptide Administration To Target the Human Brain in Health and Disease. Mol Pharm 2015;12:2767-80. [PMID: 25880274 DOI: 10.1021/acs.molpharmaceut.5b00047] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
153 Lu CT, Jin RR, Jiang YN, Lin Q, Yu WZ, Mao KL, Tian FR, Zhao YP, Zhao YZ. Gelatin nanoparticle-mediated intranasal delivery of substance P protects against 6-hydroxydopamine-induced apoptosis: an in vitro and in vivo study. Drug Des Devel Ther 2015;9:1955-62. [PMID: 25897205 DOI: 10.2147/DDDT.S77237] [Reference Citation Analysis]
154 Boido A, Ceriani V, Pontiroli AE. Glucagon for hypoglycemic episodes in insulin-treated diabetic patients: a systematic review and meta-analysis with a comparison of glucagon with dextrose and of different glucagon formulations. Acta Diabetol 2015;52:405-12. [PMID: 25323325 DOI: 10.1007/s00592-014-0665-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
155 Ding J, Li J, Mao S. Development and evaluation of vinpocetine inclusion complex for brain targeting. Asian Journal of Pharmaceutical Sciences 2015;10:114-20. [DOI: 10.1016/j.ajps.2014.08.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
156 Wermeling DP. A response to the opioid overdose epidemic: naloxone nasal spray. Drug Deliv Transl Res 2013;3:63-74. [PMID: 23734342 DOI: 10.1007/s13346-012-0092-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.7] [Reference Citation Analysis]
157 Maggio ET, Pillion DJ. High efficiency intranasal drug delivery using Intravail® alkylsaccharide absorption enhancers. Drug Deliv Transl Res 2013;3:16-25. [PMID: 25787864 DOI: 10.1007/s13346-012-0069-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
158 Balakrishnan P, Park EK, Song CK, Ko HJ, Hahn TW, Song KW, Cho HJ. Carbopol-incorporated thermoreversible gel for intranasal drug delivery. Molecules 2015;20:4124-35. [PMID: 25749681 DOI: 10.3390/molecules20034124] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
159 Marjani M, Akbarinejad V, Bagheri M. Comparison of intranasal and intramuscular ketamine-midazolam combination in cats. Veterinary Anaesthesia and Analgesia 2015;42:178-81. [DOI: 10.1111/vaa.12183] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
160 Baba M, Itaka K, Kondo K, Yamasoba T, Kataoka K. Treatment of neurological disorders by introducing mRNA in vivo using polyplex nanomicelles. Journal of Controlled Release 2015;201:41-8. [DOI: 10.1016/j.jconrel.2015.01.017] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
161 Esposito E, Ravani L, Drechsler M, Mariani P, Contado C, Ruokolainen J, Ratano P, Campolongo P, Trezza V, Nastruzzi C, Cortesi R. Cannabinoid antagonist in nanostructured lipid carriers (NLCs): design, characterization and in vivo study. Materials Science and Engineering: C 2015;48:328-36. [DOI: 10.1016/j.msec.2014.12.012] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
162 Ruigrok MJ, de Lange EC. Emerging Insights for Translational Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Studies: Towards Prediction of Nose-to-Brain Transport in Humans. AAPS J 2015;17:493-505. [PMID: 25693488 DOI: 10.1208/s12248-015-9724-x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
163 Wermeling DP. Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access. Ther Adv Drug Saf 2015;6:20-31. [PMID: 25642320 DOI: 10.1177/2042098614564776] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 11.9] [Reference Citation Analysis]
164 Zhang HY, Bi GH, Li X, Li J, Qu H, Zhang SJ, Li CY, Onaivi ES, Gardner EL, Xi ZX, Liu QR. Species differences in cannabinoid receptor 2 and receptor responses to cocaine self-administration in mice and rats. Neuropsychopharmacology 2015;40:1037-51. [PMID: 25374096 DOI: 10.1038/npp.2014.297] [Cited by in Crossref: 85] [Cited by in F6Publishing: 75] [Article Influence: 10.6] [Reference Citation Analysis]
165 Chen H, Chen CC, Acosta C, Wu SY, Sun T, Konofagou EE. A new brain drug delivery strategy: focused ultrasound-enhanced intranasal drug delivery. PLoS One 2014;9:e108880. [PMID: 25279463 DOI: 10.1371/journal.pone.0108880] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
166 Sawaengsak C, Mori Y, Yamanishi K, Srimanote P, Chaicumpa W, Mitrevej A, Sinchaipanid N. Intranasal chitosan-DNA vaccines that protect across influenza virus subtypes. International Journal of Pharmaceutics 2014;473:113-25. [DOI: 10.1016/j.ijpharm.2014.07.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
167 Gambaryan PY, Kondrasheva IG, Severin ES, Guseva AA, Kamensky AA. Increasing the Efficiency of Parkinson's Disease Treatment Using a poly(lactic-co-glycolic acid) (PLGA) Based L-DOPA Delivery System. Exp Neurobiol 2014;23:246-52. [PMID: 25258572 DOI: 10.5607/en.2014.23.3.246] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
168 Guo Q, Li P, Wang Z, Cheng Y, Wu H, Yang B, Du S, Lu Y. Brain distribution pharmacokinetics and integrated pharmacokinetics of Panax Notoginsenoside R1, Ginsenosides Rg1, Rb1, Re and Rd in rats after intranasal administration of Panax Notoginseng Saponins assessed by UPLC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2014;969:264-71. [PMID: 25203723 DOI: 10.1016/j.jchromb.2014.08.034] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
169 Fortuna A, Alves G, Serralheiro A, Sousa J, Falcão A. Intranasal delivery of systemic-acting drugs: Small-molecules and biomacromolecules. European Journal of Pharmaceutics and Biopharmaceutics 2014;88:8-27. [DOI: 10.1016/j.ejpb.2014.03.004] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 9.4] [Reference Citation Analysis]
170 Casettari L, Illum L. Chitosan in nasal delivery systems for therapeutic drugs. Journal of Controlled Release 2014;190:189-200. [DOI: 10.1016/j.jconrel.2014.05.003] [Cited by in Crossref: 207] [Cited by in F6Publishing: 178] [Article Influence: 25.9] [Reference Citation Analysis]
171 Gabal YM, Kamel AO, Sammour OA, Elshafeey AH. Effect of surface charge on the brain delivery of nanostructured lipid carriers in situ gels via the nasal route. Int J Pharm 2014;473:442-57. [PMID: 25062866 DOI: 10.1016/j.ijpharm.2014.07.025] [Cited by in Crossref: 63] [Cited by in F6Publishing: 51] [Article Influence: 7.9] [Reference Citation Analysis]
172 Upadhyay RK. Drug delivery systems, CNS protection, and the blood brain barrier. Biomed Res Int 2014;2014:869269. [PMID: 25136634 DOI: 10.1155/2014/869269] [Cited by in Crossref: 130] [Cited by in F6Publishing: 133] [Article Influence: 16.3] [Reference Citation Analysis]
173 Baird FJ, Lopata AL. The dichotomy of pathogens and allergens in vaccination approaches. Front Microbiol 2014;5:365. [PMID: 25076945 DOI: 10.3389/fmicb.2014.00365] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
174 Lu J, Fu T, Qian Y, Zhang Q, Zhu H, Pan L, Guo L, Zhang M. Distribution of α-asarone in brain following three different routes of administration in rats. Eur J Pharm Sci 2014;63:63-70. [PMID: 25008114 DOI: 10.1016/j.ejps.2014.06.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
175 Qian S, Wong YC, Zuo Z. Development, characterization and application of in situ gel systems for intranasal delivery of tacrine. International Journal of Pharmaceutics 2014;468:272-82. [DOI: 10.1016/j.ijpharm.2014.04.015] [Cited by in Crossref: 59] [Cited by in F6Publishing: 48] [Article Influence: 7.4] [Reference Citation Analysis]
176 Del Pizzo J, Callahan JM. Intranasal Medications in Pediatric Emergency Medicine: . Pediatric Emergency Care 2014;30:496-501. [DOI: 10.1097/pec.0000000000000171] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
177 Kumar A, Pandey AN, Jain SK. Nasal-nanotechnology: revolution for efficient therapeutics delivery. Drug Deliv 2016;23:681-93. [PMID: 24901207 DOI: 10.3109/10717544.2014.920431] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 6.8] [Reference Citation Analysis]
178 Verma A, Kumar N, Malviya R, Sharma PK. Emerging Trends in Noninvasive Insulin Delivery. J Pharm (Cairo) 2014;2014:378048. [PMID: 26556194 DOI: 10.1155/2014/378048] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
179 Trows S, Wuchner K, Spycher R, Steckel H. Analytical challenges and regulatory requirements for nasal drug products in europe and the u.s. Pharmaceutics 2014;6:195-219. [PMID: 24732068 DOI: 10.3390/pharmaceutics6020195] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
180 Bhavna, Md S, Ali M, Ali R, Bhatnagar A, Baboota S, Ali J. Donepezil nanosuspension intended for nose to brain targeting: In vitro and in vivo safety evaluation. Int J Biol Macromol 2014;67:418-25. [PMID: 24705169 DOI: 10.1016/j.ijbiomac.2014.03.022] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 9.1] [Reference Citation Analysis]
181 Mo R, Jiang T, Di J, Tai W, Gu Z. Emerging micro- and nanotechnology based synthetic approaches for insulin delivery. Chem Soc Rev 2014;43:3595-629. [PMID: 24626293 DOI: 10.1039/c3cs60436e] [Cited by in Crossref: 267] [Cited by in F6Publishing: 218] [Article Influence: 33.4] [Reference Citation Analysis]
182 Dresler M, Spoormaker V, Beitinger P, Czisch M, Kimura M, Steiger A, Holsboer F. Neuroscience-driven discovery and development of sleep therapeutics. Pharmacology & Therapeutics 2014;141:300-34. [DOI: 10.1016/j.pharmthera.2013.10.012] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
183 Bas S, Maquivar MG, Coutinho da Silva MA, Day ML, Daglio MC, Harguindeguy S, Titler M, Schuenemann GM. Effect of intrauterine administration of gonadotropin releasing hormone with glycerol on serum LH concentrations in lactating dairy cows. Anim Reprod Sci 2014;145:15-22. [PMID: 24461792 DOI: 10.1016/j.anireprosci.2013.12.017] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
184 Kumar M, Kakkar V, Mishra AK, Chuttani K, Kaur IP. Intranasal delivery of streptomycin sulfate (STRS) loaded solid lipid nanoparticles to brain and blood. International Journal of Pharmaceutics 2014;461:223-33. [DOI: 10.1016/j.ijpharm.2013.11.038] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
185 Leclerc L, Pourchez J, Prevot N, Vecellio L, Le Guellec S, Cottier M, Durand M. Assessing sinus aerosol deposition: benefits of SPECT-CT imaging. Int J Pharm 2014;462:135-41. [PMID: 24374606 DOI: 10.1016/j.ijpharm.2013.12.032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
186 Lee YH, Kim KH, Yoon IK, Lee KE, Chun IK, Rhie JY, Gwak HS. Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems. Eur J Drug Metab Pharmacokinet 2014;39:237-42. [DOI: 10.1007/s13318-013-0171-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
187 Wong PT, Wang SH, Ciotti S, Makidon PE, Smith DM, Fan Y, Schuler CF 4th, Baker JR Jr. Formulation and characterization of nanoemulsion intranasal adjuvants: effects of surfactant composition on mucoadhesion and immunogenicity. Mol Pharm 2014;11:531-44. [PMID: 24320221 DOI: 10.1021/mp4005029] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
188 Xiao C, Davis FJ, Chauhan BC, Viola KL, Lacor PN, Velasco PT, Klein WL, Chauhan NB. Brain transit and ameliorative effects of intranasally delivered anti-amyloid-β oligomer antibody in 5XFAD mice. J Alzheimers Dis 2013;35:777-88. [PMID: 23542865 DOI: 10.3233/JAD-122419] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
189 Irvine DJ, Su X, Kwong B. Routes of Delivery for Biological Drug Products. In: Gad SC, editor. Pharmaceutical Sciences Encyclopedia. Hoboken: John Wiley & Sons, Inc.; 2010. pp. 1-48. [DOI: 10.1002/9780470571224.pse521] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
190 Zhao YZ, Li X, Lu CT, Lin M, Chen LJ, Xiang Q, Zhang M, Jin RR, Jiang X, Shen XT, Li XK, Cai J. Gelatin nanostructured lipid carriers-mediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats. Nanomedicine 2014;10:755-64. [PMID: 24200526 DOI: 10.1016/j.nano.2013.10.009] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 6.3] [Reference Citation Analysis]
191 Vitale DC, Piazza C, Sinagra T, Urso V, Cardì F, Drago F, Salomone S. Pharmacokinetic Characterization of Tizanidine Nasal Spray, a Novel Intranasal Delivery Method for the Treatment of Skeletal Muscle Spasm. Clin Drug Investig 2013;33:885-91. [DOI: 10.1007/s40261-013-0137-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
192 Nielsen BN, Friis SM, Rømsing J, Schmiegelow K, Anderson BJ, Ferreirós N, Labocha S, Henneberg SW, Cote C. Intranasal sufentanil/ketamine analgesia in children. Paediatr Anaesth 2014;24:170-80. [DOI: 10.1111/pan.12268] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
193 Le Guellec S, Le Pennec D, Gatier S, Leclerc L, Cabrera M, Pourchez J, Diot P, Reychler G, Pitance L, Durand M, Jamar F, Vecellio L. Validation of anatomical models to study aerosol deposition in human nasal cavities. Pharm Res 2014;31:228-37. [PMID: 24065586 DOI: 10.1007/s11095-013-1157-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
194 Coué G, Hermanns I, Unger RE, Kirkpatrick CJ, Engbersen JFJ. Development and in vitro Evaluation of Antigen-Loaded Poly(amidoamine) Nanoparticles for Respiratory Epithelium Applications. ChemMedChem 2013;8:1787-94. [DOI: 10.1002/cmdc.201300307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
195 Abdel Mouez M, Zaki NM, Mansour S, Geneidi AS. Bioavailability enhancement of verapamil HCl via intranasal chitosan microspheres. Eur J Pharm Sci 2014;51:59-66. [PMID: 23999035 DOI: 10.1016/j.ejps.2013.08.029] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
196 Kamei N, Nielsen EJ, Khafagy el-S, Takeda-Morishita M. Noninvasive insulin delivery: the great potential of cell-penetrating peptides. Ther Deliv 2013;4:315-26. [PMID: 23442079 DOI: 10.4155/tde.12.164] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
197 Zhao JY, Lu Y, Du SY, Song X, Bai J, Wang Y. Comparative pharmacokinetic studies of borneol in mouse plasma and brain by different administrations. J Zhejiang Univ Sci B 2012;13:990-6. [PMID: 23225854 DOI: 10.1631/jzus.B1200142] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
198 Patil GB, Surana SJ. Fabrication and statistical optimization of surface engineered PLGA nanoparticles for naso-brain delivery of ropinirole hydrochloride: in-vitro-ex-vivo studies. J Biomater Sci Polym Ed 2013;24:1740-56. [PMID: 23705812 DOI: 10.1080/09205063.2013.798880] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
199 Jiao J, Meng N, Wang H, Zhang L. The effects of vitamins C and B12 on human nasal ciliary beat frequency. BMC Complement Altern Med 2013;13:110. [PMID: 23688196 DOI: 10.1186/1472-6882-13-110] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
200 Veening JG, Olivier B. Intranasal administration of oxytocin: behavioral and clinical effects, a review. Neurosci Biobehav Rev 2013;37:1445-65. [PMID: 23648680 DOI: 10.1016/j.neubiorev.2013.04.012] [Cited by in Crossref: 116] [Cited by in F6Publishing: 106] [Article Influence: 12.9] [Reference Citation Analysis]
201 Guastella AJ, Hickie IB, Mcguinness MM, Otis M, Woods EA, Disinger HM, Chan H, Chen TF, Banati RB. Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research. Psychoneuroendocrinology 2013;38:612-25. [DOI: 10.1016/j.psyneuen.2012.11.019] [Cited by in Crossref: 227] [Cited by in F6Publishing: 207] [Article Influence: 25.2] [Reference Citation Analysis]
202 Serova L, Tillinger A, Alaluf L, Laukova M, Keegan K, Sabban E. Single intranasal neuropeptide Y infusion attenuates development of PTSD-like symptoms to traumatic stress in rats. Neuroscience 2013;236:298-312. [DOI: 10.1016/j.neuroscience.2013.01.040] [Cited by in Crossref: 115] [Cited by in F6Publishing: 114] [Article Influence: 12.8] [Reference Citation Analysis]
203 Kürti L, Gáspár R, Márki Á, Kápolna E, Bocsik A, Veszelka S, Bartos C, Ambrus R, Vastag M, Deli MA, Szabó-Révész P. In vitro and in vivo characterization of meloxicam nanoparticles designed for nasal administration. Eur J Pharm Sci 2013;50:86-92. [PMID: 23542493 DOI: 10.1016/j.ejps.2013.03.012] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
204 Bharate SS, Vishwakarma RA. Impact of preformulation on drug development. Expert Opin Drug Deliv 2013;10:1239-57. [PMID: 23534681 DOI: 10.1517/17425247.2013.783563] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
205 Ye Y, Xu Y, Liang W, Leung GP, Cheung KH, Zheng C, Chen F, Lam JK. DNA-loaded chitosan oligosaccharide nanoparticles with enhanced permeability across Calu-3 cells. J Drug Target 2013;21:474-86. [PMID: 23480724 DOI: 10.3109/1061186X.2013.766885] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
206 Acharya SP, Pundarikakshudu K, Panchal A, Lalwani A. Preparation and evaluation of transnasal microemulsion of carbamazepine. Asian Journal of Pharmaceutical Sciences 2013;8:64-70. [DOI: 10.1016/j.ajps.2013.07.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
207 Pund S, Rasve G, Borade G. Ex vivo permeation characteristics of venlafaxine through sheep nasal mucosa. European Journal of Pharmaceutical Sciences 2013;48:195-201. [DOI: 10.1016/j.ejps.2012.10.029] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 6.1] [Reference Citation Analysis]
208 Li P, Bai J, Lu Y, Wen R, Du S. Bioavailability and Brain-Targeting of Puerarin by Different Administration Routes in Rats. Journal of Drug Delivery Science and Technology 2013;23:583-6. [DOI: 10.1016/s1773-2247(13)50088-8] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
209 Singh RM, Kumar A, Pathak K. Mucoadhesive in situ nasal gelling drug delivery systems for modulated drug delivery. Expert Opin Drug Deliv 2013;10:115-30. [PMID: 23199072 DOI: 10.1517/17425247.2013.746659] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
210 Gavini E, Rassu G, Ferraro L, Beggiato S, Alhalaweh A, Velaga S, Marchetti N, Bandiera P, Giunchedi P, Dalpiaz A. Influence of polymeric microcarriers on the in vivo intranasal uptake of an anti-migraine drug for brain targeting. Eur J Pharm Biopharm 2013;83:174-83. [PMID: 23153670 DOI: 10.1016/j.ejpb.2012.10.010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
211 Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review. Drug Deliv Transl Res 2013;3:42-62. [PMID: 23316447 DOI: 10.1007/s13346-012-0108-9] [Cited by in Crossref: 227] [Cited by in F6Publishing: 202] [Article Influence: 22.7] [Reference Citation Analysis]
212 Mantell S, Jones R, Trevethick M. Design and application of locally delivered agonists of the adenosine A(2A) receptor. Expert Rev Clin Pharmacol 2010;3:55-72. [PMID: 22111533 DOI: 10.1586/ecp.09.57] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
213 Sibley T, Jacobsen R, Salomone J. Successful Administration of Intranasal Glucagon in the Out-of-Hospital Environment. Prehospital Emergency Care 2012;17:98-102. [DOI: 10.3109/10903127.2012.717171] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
214 Kürti L, Veszelka S, Bocsik A, Ozsvári B, Puskás LG, Kittel A, Szabó-Révész P, Deli MA. Retinoic acid and hydrocortisone strengthen the barrier function of human RPMI 2650 cells, a model for nasal epithelial permeability. Cytotechnology 2013;65:395-406. [PMID: 22940916 DOI: 10.1007/s10616-012-9493-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
215 Mangas-Sanjuan V, González-Alvarez M, Gonzalez-Alvarez I, Bermejo M. Drug penetration across the blood-brain barrier: an overview. Ther Deliv 2010;1:535-62. [PMID: 22833966 DOI: 10.4155/tde.10.37] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
216 Salama HA, Mahmoud AA, Kamel AO, Abdel Hady M, Awad GA. Brain delivery of olanzapine by intranasal administration of transfersomal vesicles. J Liposome Res 2012;22:336-45. [PMID: 22881283 DOI: 10.3109/08982104.2012.700460] [Cited by in Crossref: 77] [Cited by in F6Publishing: 67] [Article Influence: 7.7] [Reference Citation Analysis]
217 Subbiah R, Ramalingam P, Ramasundaram S, Kim DY, Park K, Ramasamy MK, Choi KJ. N,N,N-Trimethyl chitosan nanoparticles for controlled intranasal delivery of HBV surface antigen. Carbohydrate Polymers 2012;89:1289-97. [DOI: 10.1016/j.carbpol.2012.04.056] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 5.6] [Reference Citation Analysis]
218 Khafagy E, Kamei N, Takeda-morishita M. Cell-penetrating Peptide-biodrug Strategy for Oral and Nasal Delivery: Review of Recent Findings. Journal of Experimental & Clinical Medicine 2012;4:198-202. [DOI: 10.1016/j.jecm.2012.06.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
219 Illum L. Nasal drug delivery — Recent developments and future prospects. Journal of Controlled Release 2012;161:254-63. [DOI: 10.1016/j.jconrel.2012.01.024] [Cited by in Crossref: 148] [Cited by in F6Publishing: 128] [Article Influence: 14.8] [Reference Citation Analysis]
220 Saladini B, Bigucci F, Cerchiara T, Gallucci MC, Luppi B. Microparticles based on chitosan/pectin polyelectrolyte complexes for nasal delivery of tacrine hydrochloride. Drug Deliv and Transl Res 2013;3:33-41. [DOI: 10.1007/s13346-012-0086-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
221 Illum L, Jordan F, Lewis AL. CriticalSorb: a novel efficient nasal delivery system for human growth hormone based on Solutol HS15. J Control Release 2012;162:194-200. [PMID: 22709592 DOI: 10.1016/j.jconrel.2012.06.014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
222 Privalova AM, Gulyaeva NV, Bukreeva TV. Intranasal administration: a prospective drug delivery route to the brain. Neurochem J 2012;6:77-88. [DOI: 10.1134/s1819712412020080] [Cited by in Crossref: 10] [Article Influence: 1.0] [Reference Citation Analysis]
223 Watts P, Smith A, Perelman M. Nasal delivery of fentanyl. Drug Deliv and Transl Res 2013;3:75-83. [DOI: 10.1007/s13346-012-0078-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
224 Kammona O, Kiparissides C. Recent advances in nanocarrier-based mucosal delivery of biomolecules. J Control Release 2012;161:781-94. [PMID: 22659331 DOI: 10.1016/j.jconrel.2012.05.040] [Cited by in Crossref: 86] [Cited by in F6Publishing: 70] [Article Influence: 8.6] [Reference Citation Analysis]
225 Brayden DJ, Bzik VA, Lewis AL, Illum L. CriticalSorb™ Promotes Permeation of Flux Markers Across Isolated Rat Intestinal Mucosae and Caco-2 Monolayers. Pharm Res 2012;29:2543-54. [DOI: 10.1007/s11095-012-0785-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
226 Cho H, Balakrishnan P, Lin H, Choi M, Kim D. Application of biopharmaceutics classification system (BCS) in drug transport studies across human respiratory epithelial cell monolayers. Journal of Pharmaceutical Investigation 2012;42:147-53. [DOI: 10.1007/s40005-012-0020-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
227 Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 2012;64:614-28. [PMID: 22119441 DOI: 10.1016/j.addr.2011.11.002] [Cited by in Crossref: 631] [Cited by in F6Publishing: 563] [Article Influence: 63.1] [Reference Citation Analysis]
228 Li W, Zhou Y, Zhao N, Hao B, Wang X, Kong P. Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes. Environ Toxicol Pharmacol 2012;34:272-9. [PMID: 22613079 DOI: 10.1016/j.etap.2012.04.012] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
229 Kiparissides C, Kammona O. Nanoscale carriers for targeted delivery of drugs and therapeutic biomolecules. Can J Chem Eng 2013;91:638-51. [DOI: 10.1002/cjce.21685] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
230 Hardmeier M, Zimmermann R, Rüegg S, Pflüger M, Deuster S, Suter K, Donzelli M, Drewe J, Krähenbühl S, Fuhr P, Haschke M. Intranasal Midazolam: Pharmacokinetics and Pharmacodynamics Assessed by Quantitative EEG in Healthy Volunteers. Clin Pharmacol Ther 2012;91:856-62. [DOI: 10.1038/clpt.2011.316] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
231 Grassin-Delyle S, Buenestado A, Naline E, Faisy C, Blouquit-Laye S, Couderc LJ, Le Guen M, Fischler M, Devillier P. Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol Ther 2012;134:366-79. [PMID: 22465159 DOI: 10.1016/j.pharmthera.2012.03.003] [Cited by in Crossref: 182] [Cited by in F6Publishing: 149] [Article Influence: 18.2] [Reference Citation Analysis]
232 Zhao Y, Brown MB, Khengar RH, Traynor MJ, Barata P, Jones SA. Pharmacokinetic evaluation of intranasally administered vinyl polymer-coated lorazepam microparticles in rabbits. AAPS J 2012;14:218-24. [PMID: 22396304 DOI: 10.1208/s12248-012-9325-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
233 Hanson LR, Fine JM, Hoekman JD, Nguyen TM, Burns RB, Martinez PM, Pohl J, Frey WH. Intranasal delivery of growth differentiation factor 5 to the central nervous system. Drug Delivery 2012;19:149-54. [DOI: 10.3109/10717544.2012.657720] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
234 Ozsoy Y, Güngör S. Nasal route: an alternative approach for antiemetic drug delivery. Expert Opin Drug Deliv 2011;8:1439-53. [PMID: 22004793 DOI: 10.1517/17425247.2011.607437] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
235 Schumacher M, Hussain R, Gago N, Oudinet JP, Mattern C, Ghoumari AM. Progesterone synthesis in the nervous system: implications for myelination and myelin repair. Front Neurosci 2012;6:10. [PMID: 22347156 DOI: 10.3389/fnins.2012.00010] [Cited by in Crossref: 117] [Cited by in F6Publishing: 106] [Article Influence: 11.7] [Reference Citation Analysis]
236 Chao OY, Mattern C, De Souza Silva AM, Weßler J, Ruocco LA, Nikolaus S, Huston JP, Pum ME. Intranasally applied l-DOPA alleviates parkinsonian symptoms in rats with unilateral nigro-striatal 6-OHDA lesions. Brain Research Bulletin 2012;87:340-5. [DOI: 10.1016/j.brainresbull.2011.11.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
237 Hanson LR, Fine JM, Renner DB, Svitak AL, Burns RB, Nguyen TM, Tuttle NJ, Marti DL, Panter SS, Frey WH. Intranasal delivery of deferoxamine reduces spatial memory loss in APP/PS1 mice. Drug Deliv and Transl Res 2012;2:160-8. [DOI: 10.1007/s13346-011-0050-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
238 Dale O. Intranasal administration of opioids/fentanyl-Physiological and pharmacological aspects. European Journal of Pain Supplements 2010;4:187-90. [DOI: 10.1016/j.eujps.2010.06.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
239 Cho HJ, Ku WS, Termsarasab U, Yoon I, Chung CW, Moon HT, Kim DD. Development of udenafil-loaded microemulsions for intranasal delivery: in vitro and in vivo evaluations. Int J Pharm 2012;423:153-60. [PMID: 22209996 DOI: 10.1016/j.ijpharm.2011.12.028] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
240 Bahadur S, Pathak K. Physicochemical and physiological considerations for efficient nose-to-brain targeting. Expert Opinion on Drug Delivery 2011;9:19-31. [DOI: 10.1517/17425247.2012.636801] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 5.6] [Reference Citation Analysis]
241 Samson G, García de la Calera A, Dupuis-Girod S, Faure F, Decullier E, Paintaud G, Vignault C, Scoazec JY, Pivot C, Plauchu H, Pirot F. Ex vivo study of bevacizumab transport through porcine nasal mucosa. Eur J Pharm Biopharm 2012;80:465-9. [PMID: 22120685 DOI: 10.1016/j.ejpb.2011.11.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
242 Colombo G, Lorenzini L, Zironi E, Galligioni V, Sonvico F, Balducci AG, Pagliuca G, Giuliani A, Calzà L, Scagliarini A. Brain distribution of ribavirin after intranasal administration. Antiviral Res 2011;92:408-14. [PMID: 22001322 DOI: 10.1016/j.antiviral.2011.09.012] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 4.9] [Reference Citation Analysis]
243 Scherließ R. Delivery of antigens used for vaccination: recent advances and challenges. Therapeutic Delivery 2011;2:1351-68. [DOI: 10.4155/tde.11.80] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
244 Xia H, Gao X, Gu G, Liu Z, Zeng N, Hu Q, Song Q, Yao L, Pang Z, Jiang X, Chen J, Chen H. Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration. Biomaterials 2011;32:9888-98. [PMID: 21937105 DOI: 10.1016/j.biomaterials.2011.09.004] [Cited by in Crossref: 100] [Cited by in F6Publishing: 95] [Article Influence: 9.1] [Reference Citation Analysis]
245 Xi ZX, Peng XQ, Li X, Song R, Zhang HY, Liu QR, Yang HJ, Bi GH, Li J, Gardner EL. Brain cannabinoid CB₂ receptors modulate cocaine's actions in mice. Nat Neurosci 2011;14:1160-6. [PMID: 21785434 DOI: 10.1038/nn.2874] [Cited by in Crossref: 258] [Cited by in F6Publishing: 244] [Article Influence: 23.5] [Reference Citation Analysis]
246 Cho HJ, Balakrishnan P, Chung SJ, Shim CK, Kim DD. Evaluation of protein stability and in vitro permeation of lyophilized polysaccharides-based microparticles for intranasal protein delivery. Int J Pharm 2011;416:77-84. [PMID: 21703339 DOI: 10.1016/j.ijpharm.2011.06.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
247 Che MM, Chanda S, Song J, Doctor BP, Rezk PE, Sabnekar P, Perkins MW, Sciuto AM, Nambiar MP. Aerosolized scopolamine protects against microinstillation inhalation toxicity to sarin in guinea pigs. Toxicology Mechanisms and Methods 2011;21:463-72. [DOI: 10.3109/15376516.2011.562258] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
248 Malerba F, Paoletti F, Capsoni S, Cattaneo A. Intranasal delivery of therapeutic proteins for neurological diseases. Expert Opin Drug Deliv 2011;8:1277-96. [PMID: 21619468 DOI: 10.1517/17425247.2011.588204] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
249 Traynor MJ, Zhao Y, Brown MB, Jones SA. Vinyl polymer-coated lorazepam particles for drug delivery to the airways. International Journal of Pharmaceutics 2011;410:9-16. [DOI: 10.1016/j.ijpharm.2011.02.053] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
250 Gavini E, Rassu G, Ferraro L, Generosi A, Rau JV, Brunetti A, Giunchedi P, Dalpiaz A. Influence of Chitosan Glutamate on the in vivo Intranasal Absorption of Rokitamycin from Microspheres. Journal of Pharmaceutical Sciences 2011;100:1488-502. [DOI: 10.1002/jps.22382] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
251 Jayachandra Babu R, Dayal PP, Pawar K, Singh M. Nose-to-brain transport of melatonin from polymer gel suspensions: a microdialysis study in rats. J Drug Target 2011;19:731-40. [PMID: 21428693 DOI: 10.3109/1061186X.2011.558090] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
252 Eskandari S, Varshosaz J, Minaiyan M, Tabbakhian M. Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model. Int J Nanomedicine 2011;6:363-71. [PMID: 21499426 DOI: 10.2147/IJN.S15881] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
253 Cho HJ, Choi MK, Lin H, Kim JS, Chung SJ, Shim CK, Kim DD. Expression and functional activity of P-glycoprotein in passaged primary human nasal epithelial cell monolayers cultured by the air-liquid interface method for nasal drug transport study. J Pharm Pharmacol 2011;63:385-91. [PMID: 21749386 DOI: 10.1111/j.2042-7158.2010.01221.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
254 Zhang G, Shi G, Tan H, Kang Y, Cui H. Intranasal administration of testosterone increased immobile-sniffing, exploratory behavior, motor behavior and grooming behavior in rats. Horm Behav 2011;59:477-83. [PMID: 21281642 DOI: 10.1016/j.yhbeh.2011.01.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
255 Musulin SE, Mariani CL, Papich MG. Diazepam pharmacokinetics after nasal drop and atomized nasal administration in dogs: Intranasal diazepam pharmacokinetics in dogs. Journal of Veterinary Pharmacology and Therapeutics 2011;34:17-24. [DOI: 10.1111/j.1365-2885.2010.01186.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
256 Watts PJ, Smith A. Re-formulating drugs and vaccines for intranasal delivery: maximum benefits for minimum risks? Drug Discovery Today 2011;16:4-7. [DOI: 10.1016/j.drudis.2010.11.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
257 Scherließ R, Trows S. Novel Formulation Concept for Particulate Uptake of Vaccines via the Nasal Associated Lymphoid Tissue. Procedia in Vaccinology 2011;4:113-9. [DOI: 10.1016/j.provac.2011.07.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
258 . In vitro Nasal Cell Culture Systems for Drug Transport Studies. Journal of Pharmaceutical Investigation 2010;40:321-32. [DOI: 10.4333/kps.2010.40.6.321] [Cited by in Crossref: 13] [Article Influence: 1.1] [Reference Citation Analysis]
259 Genc S, Zadeoglulari Z, Oner MG, Genc K, Digicaylioglu M. Intranasal erythropoietin therapy in nervous system disorders. Expert Opinion on Drug Delivery 2010;8:19-32. [DOI: 10.1517/17425247.2011.540236] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
260 Devillier P, Grassin-Delyle S, Naline E, Buenestado A, Blouquit-Laye S, Advenier C. [Intranasal delivery of systemic drugs: a new route for opioid drugs]. Therapie 2010;65:475-81. [PMID: 21144483 DOI: 10.2515/therapie/2010052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
261 Mathias NR, Hussain MA. Non-invasive systemic drug delivery: developability considerations for alternate routes of administration. J Pharm Sci 2010;99:1-20. [PMID: 19499570 DOI: 10.1002/jps.21793] [Cited by in Crossref: 92] [Cited by in F6Publishing: 74] [Article Influence: 7.7] [Reference Citation Analysis]
262 Lorenzi JC, Trombone AP, Rocha CD, Almeida LP, Lousada RL, Malardo T, Fontoura IC, Rossetti RA, Gembre AF, Silva AM, Silva CL, Coelho-Castelo AA. Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosis. BMC Biotechnol 2010;10:77. [PMID: 20961459 DOI: 10.1186/1472-6750-10-77] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
263 Doughty DV, Vibbert C, Kewalramani A, Bollinger ME, Dalby RN. Automated actuation of nasal spray products: determination and comparison of adult and pediatric settings. Drug Dev Ind Pharm 2011;37:359-66. [PMID: 20923391 DOI: 10.3109/03639045.2010.520321] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
264 Bleier BS. Novel topical therapeutics. Otolaryngol Clin North Am 2010;43:539-49, viii-ix. [PMID: 20525509 DOI: 10.1016/j.otc.2010.02.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
265 Cho HJ, Balakrishnan P, Shim WS, Chung SJ, Shim CK, Kim DD. Characterization and in vitro evaluation of freeze-dried microparticles composed of granisetron-cyclodextrin complex and carboxymethylcellulose for intranasal delivery. Int J Pharm 2010;400:59-65. [PMID: 20801202 DOI: 10.1016/j.ijpharm.2010.08.030] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
266 Piao H, Balakrishnan P, Cho H, Kim H, Kim Y, Chung S, Shim C, Kim D. Preparation and evaluation of fexofenadine microemulsions for intranasal delivery. International Journal of Pharmaceutics 2010;395:309-16. [DOI: 10.1016/j.ijpharm.2010.05.041] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
267 Alam MI, Beg S, Samad A, Baboota S, Kohli K, Ali J, Ahuja A, Akbar M. Strategy for effective brain drug delivery. European Journal of Pharmaceutical Sciences 2010;40:385-403. [DOI: 10.1016/j.ejps.2010.05.003] [Cited by in Crossref: 214] [Cited by in F6Publishing: 191] [Article Influence: 17.8] [Reference Citation Analysis]
268 Lile JA, Babalonis S, Emurian C, Martin CA, Wermeling DP, Kelly TH. Comparison of the behavioral and cardiovascular effects of intranasal and oral d-amphetamine in healthy human subjects. J Clin Pharmacol 2011;51:888-98. [PMID: 20671295 DOI: 10.1177/0091270010375956] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
269 Padowski JM, Pollack GM. Examination of the Ability of the Nasal Administration Route to Confer a Brain Exposure Advantage for Three Chemical Inhibitors of P-Glycoprotein. Journal of Pharmaceutical Sciences 2010;99:3226-33. [DOI: 10.1002/jps.22070] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
270 Luppi B, Bigucci F, Cerchiara T, Zecchi V. Chitosan-based hydrogels for nasal drug delivery: from inserts to nanoparticles. Expert Opinion on Drug Delivery 2010;7:811-28. [DOI: 10.1517/17425247.2010.495981] [Cited by in Crossref: 73] [Cited by in F6Publishing: 58] [Article Influence: 6.1] [Reference Citation Analysis]
271 Dhuria SV, Hanson LR, Frey WH 2nd. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2010;99:1654-1673. [PMID: 19877171 DOI: 10.1002/jps.21924] [Cited by in Crossref: 658] [Cited by in F6Publishing: 614] [Article Influence: 54.8] [Reference Citation Analysis]
272 Vaddady PK, Meibohm B. Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics of Protein Therapeutics. Encyclopedia of Industrial Biotechnology. Hoboken: John Wiley & Sons, Inc.; 2009. [DOI: 10.1002/9780470054581.eib110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
273 Veldhorst-Janssen NM, Fiddelers AA, van der Kuy PH, Neef C, Marcus MA. A review of the clinical pharmacokinetics of opioids, benzodiazepines, and antimigraine drugs delivered intranasally. Clin Ther 2009;31:2954-87. [PMID: 20110035 DOI: 10.1016/j.clinthera.2009.12.015] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
274 Harvey AJ, Kaestner SA, Sutter DE, Harvey NG, Mikszta JA, Pettis RJ. Microneedle-based intradermal delivery enables rapid lymphatic uptake and distribution of protein drugs. Pharm Res 2011;28:107-16. [PMID: 20354765 DOI: 10.1007/s11095-010-0123-9] [Cited by in Crossref: 93] [Cited by in F6Publishing: 81] [Article Influence: 7.8] [Reference Citation Analysis]
275 Jiang L, Gao L, Wang X, Tang L, Ma J. The application of mucoadhesive polymers in nasal drug delivery. Drug Development and Industrial Pharmacy 2010;36:323-36. [DOI: 10.3109/03639040903170750] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
276 Agu RU, Obimah DU, Lyzenga WJ, Jorissen M, Massoud E, Verbeke N. Specific aminopeptidases of excised human nasal epithelium and primary culture: a comparison of functional characteristics and gene transcripts expression. Journal of Pharmacy and Pharmacology 2009;61:599-606. [DOI: 10.1211/jpp.61.05.0008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
277 Mallants R, Vlaeminck V, Jorissen M, Augustijns P. An improved primary human nasal cell culture for the simultaneous determination of transepithelial transport and ciliary beat frequency. Journal of Pharmacy and Pharmacology 2009;61:883-90. [DOI: 10.1211/jpp.61.07.0007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
278 Benedetti MS, Whomsley R, Poggesi I, Cawello W, Mathy FX, Delporte ML, Papeleu P, Watelet JB. Drug metabolism and pharmacokinetics. Drug Metab Rev 2009;41:344-90. [PMID: 19601718 DOI: 10.1080/10837450902891295] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
279 Kerr D, Kelly AM, Dietze P, Jolley D, Barger B. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction 2009;104:2067-74. [PMID: 19922572 DOI: 10.1111/j.1360-0443.2009.02724.x] [Cited by in Crossref: 108] [Cited by in F6Publishing: 94] [Article Influence: 8.3] [Reference Citation Analysis]
280 Kim TK, Kang W, Chun IK, Oh SY, Lee YH, Gwak HS. Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems. European Journal of Pharmaceutical Sciences 2009;38:525-32. [DOI: 10.1016/j.ejps.2009.09.019] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
281 Amoako-Tuffour M, Yeung PK, Agu RU. Permeation of losartan across human respiratory epithelium: an in vitro study with Calu-3 cells. Acta Pharm 2009;59:395-405. [PMID: 19919929 DOI: 10.2478/v10007-009-0038-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
282 Kang ML, Cho CS, Yoo HS. Application of chitosan microspheres for nasal delivery of vaccines. Biotechnology Advances 2009;27:857-65. [DOI: 10.1016/j.biotechadv.2009.06.007] [Cited by in Crossref: 83] [Cited by in F6Publishing: 73] [Article Influence: 6.4] [Reference Citation Analysis]
283 Attkins NJ, Heatherington AC, Phipps J, Verrier H, Huyghe I. Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061. Xenobiotica 2009;39:523-33. [PMID: 19480558 DOI: 10.1080/00498250902893775] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
284 Skretting A, Djupesland PG. A new method for scintigraphic quantification of deposition and clearance in anatomical regions of the human nose. Nucl Med Commun 2009;30:629-38. [PMID: 19531967 DOI: 10.1097/MNM.0b013e32832c32b3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
285 Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. International Journal of Pharmaceutics 2009;379:146-57. [DOI: 10.1016/j.ijpharm.2009.06.019] [Cited by in Crossref: 381] [Cited by in F6Publishing: 331] [Article Influence: 29.3] [Reference Citation Analysis]
286 Kharenko EA, Larionova NI, Demina NB. Mucoadhesive drug delivery systems (Review). Pharm Chem J 2009;43:200-8. [DOI: 10.1007/s11094-009-0271-6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
287 Khafagy el-S, Morishita M, Kamei N, Eda Y, Ikeno Y, Takayama K. Efficiency of cell-penetrating peptides on the nasal and intestinal absorption of therapeutic peptides and proteins. Int J Pharm 2009;381:49-55. [PMID: 19646515 DOI: 10.1016/j.ijpharm.2009.07.022] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 4.8] [Reference Citation Analysis]
288 Bonferoni MC, Sandri G, Rossi S, Ferrari F, Caramella C. Chitosan and its salts for mucosal and transmucosal delivery. Expert Opinion on Drug Delivery 2009;6:923-39. [DOI: 10.1517/17425240903114142] [Cited by in Crossref: 66] [Cited by in F6Publishing: 58] [Article Influence: 5.1] [Reference Citation Analysis]
289 Hafner A, Lovrić J, Voinovich D, Filipović-Grcić J. Melatonin-loaded lecithin/chitosan nanoparticles: physicochemical characterisation and permeability through Caco-2 cell monolayers. Int J Pharm 2009;381:205-13. [PMID: 19596430 DOI: 10.1016/j.ijpharm.2009.07.001] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 5.8] [Reference Citation Analysis]
290 Xi ZX, Kiyatkin M, Li X, Peng XQ, Wiggins A, Spiller K, Li J, Gardner EL. N-acetylaspartylglutamate (NAAG) inhibits intravenous cocaine self-administration and cocaine-enhanced brain-stimulation reward in rats. Neuropharmacology 2010;58:304-13. [PMID: 19559037 DOI: 10.1016/j.neuropharm.2009.06.016] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
291 Wermeling DP. Intranasal delivery of antiepileptic medications for treatment of seizures. Neurotherapeutics 2009;6:352-8. [PMID: 19332330 DOI: 10.1016/j.nurt.2009.01.002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 44] [Article Influence: 4.8] [Reference Citation Analysis]
292 Watts P, Smith A. PecSys: in situ gelling system for optimised nasal drug delivery. Expert Opinion on Drug Delivery 2009;6:543-52. [DOI: 10.1517/17425240902939135] [Cited by in Crossref: 80] [Cited by in F6Publishing: 61] [Article Influence: 6.2] [Reference Citation Analysis]
293 Pedro AS, Cabral-albuquerque E, Ferreira D, Sarmento B. Chitosan: An option for development of essential oil delivery systems for oral cavity care? Carbohydrate Polymers 2009;76:501-8. [DOI: 10.1016/j.carbpol.2008.12.016] [Cited by in Crossref: 97] [Cited by in F6Publishing: 72] [Article Influence: 7.5] [Reference Citation Analysis]
294 Horvát S, Fehér A, Wolburg H, Sipos P, Veszelka S, Tóth A, Kis L, Kurunczi A, Balogh G, Kürti L, Erős I, Szabó-révész P, Deli MA. Sodium hyaluronate as a mucoadhesive component in nasal formulation enhances delivery of molecules to brain tissue. European Journal of Pharmaceutics and Biopharmaceutics 2009;72:252-9. [DOI: 10.1016/j.ejpb.2008.10.009] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 4.4] [Reference Citation Analysis]
295 Gavini E, Rassu G, Haukvik T, Lanni C, Racchi M, Giunchedi P. Mucoadhesive microspheres for nasal administration of cyclodextrins. J Drug Target 2009;17:168-79. [PMID: 18985506 DOI: 10.1080/10611860802556842] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
296 Andrews GP, Laverty TP, Jones DS. Mucoadhesive polymeric platforms for controlled drug delivery. European Journal of Pharmaceutics and Biopharmaceutics 2009;71:505-18. [DOI: 10.1016/j.ejpb.2008.09.028] [Cited by in Crossref: 462] [Cited by in F6Publishing: 384] [Article Influence: 35.5] [Reference Citation Analysis]
297 Mrsny RJ. Lessons from nature: "Pathogen-Mimetic" systems for mucosal nano-medicines. Adv Drug Deliv Rev 2009;61:172-92. [PMID: 19146895 DOI: 10.1016/j.addr.2008.09.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
298 de Souza Silva M, Mattern C, Topic B, Buddenberg T, Huston J. Dopaminergic and serotonergic activity in neostriatum and nucleus accumbens enhanced by intranasal administration of testosterone. European Neuropsychopharmacology 2009;19:53-63. [DOI: 10.1016/j.euroneuro.2008.08.003] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 5.9] [Reference Citation Analysis]
299 Costantino HR, Leonard AK, Brandt G, Johnson PH, Quay SC. Intranasal administration of acetylcholinesterase inhibitors. BMC Neurosci 2008;9 Suppl 3:S6. [PMID: 19091003 DOI: 10.1186/1471-2202-9-S3-S6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
300 Wermeling DP, Record KA, Archer SM, Rudy AC. A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation. Epilepsy Res 2009;83:124-32. [PMID: 19046855 DOI: 10.1016/j.eplepsyres.2008.10.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
301 Jug M, Bećirević-laćan M. Development of a Cyclodextrin-Based Nasal Delivery System for Lorazepam. Drug Development and Industrial Pharmacy 2008;34:817-26. [DOI: 10.1080/03639040801926063] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
302 de Souza Silva MA, Topic B, Huston JP, Mattern C. Intranasal administration of progesterone increases dopaminergic activity in amygdala and neostriatum of male rats. Neuroscience 2008;157:196-203. [PMID: 18824215 DOI: 10.1016/j.neuroscience.2008.09.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
303 Moeller EH, Jorgensen L. Alternative routes of administration for systemic delivery of protein pharmaceuticals. Drug Discovery Today: Technologies 2008;5:e89-94. [DOI: 10.1016/j.ddtec.2008.11.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
304 Miller JL, Ashford JW, Archer SM, Rudy AC, Wermeling DP. Comparison of Intranasal Administration of Haloperidol with Intravenous and Intramuscular Administration: A Pilot Pharmacokinetic Study. Pharmacotherapy 2008;28:875-82. [DOI: 10.1592/phco.28.7.875] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
305 Fayrer-hosken R. Controlling Animal Populations Using Anti-Fertility Vaccines. Reproduction in Domestic Animals 2008;43:179-85. [DOI: 10.1111/j.1439-0531.2008.01159.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
306 Mitchell RL, Costantino HR, Sileno A, Duffy T, Brandt G, Quay SC. Intranasal insulin: PK profile designed specifically for prandial treatment of Type 2 Diabetes. Drug Dev Res 2008;69:143-52. [DOI: 10.1002/ddr.20243] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
307 Fong TM. Development of anti-obesity agents: drugs that target neuropeptide and neurotransmitter systems. Expert Opin Investig Drugs 2008;17:321-5. [PMID: 18321231 DOI: 10.1517/13543784.17.3.321] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
308 Johnson PH, Frank D, Costantino HR. Discovery of tight junction modulators: significance for drug development and delivery. Drug Discovery Today 2008;13:261-7. [DOI: 10.1016/j.drudis.2007.10.023] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]